TY - JOUR
T1 - NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human
AU - Yu, Jianhua
AU - Mitsui, Takeki
AU - Wei, Min
AU - Mao, Hsiaoyin
AU - Butchar, Jonathan P.
AU - Shah, Mithun Vinod
AU - Zhang, Jianying
AU - Mishra, Anjali
AU - Alvarez-Breckenridge, Christopher
AU - Liu, Xingluo
AU - Liu, Shujun
AU - Yokohama, Akihiko
AU - Trotta, Rossana
AU - Marcucci, Guido
AU - Benson, Don M.
AU - Loughran, Thomas P.
AU - Tridandapani, Susheela
AU - Caligiuri, Michael A.
PY - 2011/4/1
Y1 - 2011/4/1
N2 - IL-15 may have a role in the development of T cell large granular lymphocyte (T-LGL) or NKT leukemias. However, the mechanisms of action and the identity of the cell subset that undergoes leukemic transformation remain elusive. Here we show that in both mice and humans, NKp46 expression marks a minute population of WT NKT cells with higher activity and potency to become leukemic. Virtually 100% of T-LGL leukemias in IL-15 transgenic mice expressed NKp46, as did a majority of human T-LGL leukemias. The minute NKp46 + NKT population, but not the NKp46 - NKT population, was selectively expanded by overexpression of endogenous IL-15. Importantly, IL-15 transgenic NKp46- NKT cells did not become NKp46+ in vivo, suggesting that NKp46 + T-LGL leukemia cells were the malignant counterpart of the minute WT NKp46 + NKT population. Mechanistically, NKp46 + NKT cells possessed higher responsiveness to IL-15 in vitro and in vivo compared with that of their NKp46 - NKT counterparts. Furthermore, interruption of IL-15 signaling using a neutralizing antibody could prevent LGL leukemia in IL-15 transgenic mice. Collectively, our data demonstrate that NKp46 identifies a functionally distinct NKT subset in mice and humans that appears to be directly susceptible to leukemic transformation when IL-15 is overexpressed. Thus, IL-15 signaling and NKp46 may be useful targets in the treatment of patients with T-LGL or NKT leukemia.
AB - IL-15 may have a role in the development of T cell large granular lymphocyte (T-LGL) or NKT leukemias. However, the mechanisms of action and the identity of the cell subset that undergoes leukemic transformation remain elusive. Here we show that in both mice and humans, NKp46 expression marks a minute population of WT NKT cells with higher activity and potency to become leukemic. Virtually 100% of T-LGL leukemias in IL-15 transgenic mice expressed NKp46, as did a majority of human T-LGL leukemias. The minute NKp46 + NKT population, but not the NKp46 - NKT population, was selectively expanded by overexpression of endogenous IL-15. Importantly, IL-15 transgenic NKp46- NKT cells did not become NKp46+ in vivo, suggesting that NKp46 + T-LGL leukemia cells were the malignant counterpart of the minute WT NKp46 + NKT population. Mechanistically, NKp46 + NKT cells possessed higher responsiveness to IL-15 in vitro and in vivo compared with that of their NKp46 - NKT counterparts. Furthermore, interruption of IL-15 signaling using a neutralizing antibody could prevent LGL leukemia in IL-15 transgenic mice. Collectively, our data demonstrate that NKp46 identifies a functionally distinct NKT subset in mice and humans that appears to be directly susceptible to leukemic transformation when IL-15 is overexpressed. Thus, IL-15 signaling and NKp46 may be useful targets in the treatment of patients with T-LGL or NKT leukemia.
UR - http://www.scopus.com/inward/record.url?scp=79953310104&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79953310104&partnerID=8YFLogxK
U2 - 10.1172/JCI43242
DO - 10.1172/JCI43242
M3 - Article
C2 - 21364281
AN - SCOPUS:79953310104
SN - 0021-9738
VL - 121
SP - 1456
EP - 1470
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 4
ER -